Athersys

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases.  The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Company Growth (employees)
Type
Public
HQ
Cleveland, US
Founded
1995
Size (employees)
60 (est)
Athersys was founded in 1995 and is headquartered in Cleveland, US

Key People at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann Jr

William Lehmann Jr

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Laura Campbell

Laura Campbell

Controller
Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Office Locations

Athersys has offices in Cleveland and Canton
Cleveland, US (HQ)
3201 Carnegie Ave
Canton, US
250 Royall St

Athersys Data and Metrics

Athersys Financial Metrics

Athersys's revenue was reported to be $1.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.5 m

EBIT (Q1, 2017)

(6.4 m)

Market capitalization (22-Aug-2017)

182.3 m

Cash (31-Mar-2017)

31.9 m
Athersys's current market capitalization is $182.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.4 m1.6 m11.9 m17.3 m

Revenue growth, %

(33%)636%45%

EBIT

(24.5 m)(29 m)(17.2 m)(15 m)

EBIT margin, %

(1003%)(1788%)(144%)(87%)

Pre tax profit

(30.7 m)(22.3 m)(16.5 m)(15.4 m)

Net Income

(30.7 m)(22.1 m)(16.4 m)(15.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

388 k293 k731 k216 k396 k15.5 m595 k311 k1.5 m

R&D expense

5.8 m5.8 m5.7 m5.3 m5.1 m6.7 m5.8 m5.3 m5.6 m

General and administrative expense

1.8 m1.7 m1.9 m1.9 m1.9 m2 m2 m1.8 m2.1 m

Operating expense total

7.6 m7.5 m7.6 m7.2 m7 m8.7 m7.8 m7.1 m7.7 m

EBIT

(7.3 m)(7.3 m)(6.9 m)(7 m)(6.7 m)6.7 m(7.3 m)(6.2 m)(6.4 m)

EBIT margin, %

(1878%)(2481%)(943%)(3256%)(1692%)43%(1224%)(1998%)(435%)

Pre tax profit

4.7 m(7 m)(6 m)

Income tax expense

9 k13 k12 k13 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

31.9 m26.1 m23 m14.8 m

Accounts Receivable

520 k694 k361 k598 k

Current Assets

32.9 m27.2 m23.8 m16.3 m

Total Assets

34.2 m28.7 m25.1 m19.1 m

Accounts Payable

2.2 m2.8 m2.7 m4.8 m

Total Debt

176 k183 k190 k

Current Liabilities

4.4 m4.7 m4.8 m6.9 m

Additional Paid-in Capital

284.3 m307.3 m322.6 m329.4 m

Retained Earnings

(264.4 m)(286.5 m)(302.9 m)(318.3 m)

Total Equity

19.8 m20.9 m19.7 m11.2 m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.7 x1.4 x1.3 x1.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

38.8 m32.4 m35.5 m32.3 m28.5 m30.4 m13.8 m8.3 m31.9 m

Accounts Receivable

715 k665 k298 k1.8 m

Current Assets

39.8 m33.4 m38.7 m35.1 m29.2 m31.5 m25.7 m20.5 m34.9 m

Total Assets

41.1 m34.8 m40.2 m36.5 m30.6 m33 m27.9 m23.3 m37.6 m

Accounts Payable

2.8 m2.9 m2.7 m2.3 m2.6 m3.3 m4.2 m3.6 m6.6 m

Current Liabilities

4.5 m4.8 m14.2 m14 m14.3 m4.7 m5.7 m5.2 m8.4 m

Additional Paid-in Capital

306 m306.7 m317.9 m321.3 m322 m323.5 m324.8 m327.1 m353.1 m

Retained Earnings

(275.2 m)(280 m)(299 m)(300 m)(306.5 m)(298.2 m)(305.1 m)(311.2 m)(324 m)

Total Equity

30.9 m26.8 m19 m21.4 m15.5 m25.4 m19.8 m16 m29.2 m

Financial Leverage

1.3 x1.3 x2.1 x1.7 x2 x1.3 x1.4 x1.5 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(30.7 m)(22.1 m)(16.4 m)(15.3 m)

Depreciation and Amortization

346 k360 k267 k382 k

Accounts Receivable

(30 k)(174 k)333 k(237 k)

Accounts Payable

(196 k)335 k(296 k)2.4 m

Cash From Operating Activities

(22.8 m)(25.8 m)(13.8 m)(10.9 m)

Cash From Investing Activities

(385 k)(297 k)(132 k)(1.1 m)

Cash From Financing Activities

29.6 m20.3 m10.8 m3.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Depreciation and Amortization

93 k91 k70 k65 k66 k68 k67 k114 k164 k

Accounts Receivable

715 k665 k298 k1.8 m

Accounts Payable

2.8 m2.9 m2.7 m2.3 m2.6 m3.3 m4.2 m3.6 m6.6 m
USDY, 2017

Revenue/Employee

24.5 k

Financial Leverage

1.3 x

Athersys Operating Metrics

Athersys's Patent Applications was reported to be 170 in FY, 2016
FY, 2016

Patents Issued

200

Patents (US)

21

Patent Applications

170

Athersys Market Value History

Traffic Overview of Athersys

Athersys Online and Social Media Presence

Athersys Company Life and Culture

You may also be interested in